molm 13  (DSMZ)

Journal: The Journal of Biological Chemistry

Article Title: Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression

doi: 10.1016/j.jbc.2026.112204

Figure Lengend Snippet: MYCBP2 knockdown inhibits AML cell proliferation and induces apoptosis . A , qRT-PCR and Western Blot validation of MYCBP2 siRNA knockdown in MOLM-13 and HL-60 cells. B , CCK-8 assay: reduced viability post-MYCBP2 knockdown. C–D , colony formation assay: suppressed clonogenicity in siRNA-treated cells. E–F , flow cytometry: increased apoptosis (Annexin V/PI staining) in MYCBP2-knockdown cells. n = 3, mean ± SD; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: MOLM-13 and HL-60 cells (purchased from Wuhan Procell Life Science & Technology Co., Ltd) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, maintained at 37 °C in a 5% CO 2 incubator until reaching 70% to 80 confluence.

Techniques: Knockdown, Quantitative RT-PCR, Western Blot, Biomarker Discovery, CCK-8 Assay, Colony Assay, Flow Cytometry, Staining

Journal: The Journal of Biological Chemistry

Article Title: Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression

doi: 10.1016/j.jbc.2026.112204

Figure Lengend Snippet: MYCBP2 destabilizes KIF14 via ubiquitin-proteasome system . A , GSEA associating MYCBP2 with ubiquitin-mediated proteolysis. B–C , UbiBrowser prediction of MYCBP2-KIF14 interaction (confidence score: 0.746). D , RT-qPCR confirms no significant change in KIF14 mRNA expression after MYCBP2 knockdown (n.s., p > 0.05). E , Western blot analysis shows increased KIF14 protein levels in MYCBP2-knockdown MOLM-13 and HL-60 cells (∗ p < 0.05 vs. si-NC). F , Co-IP confirming endogenous MYCBP2-KIF14 interaction. G , exogenous co-IP in 293T cells (Myc-MYCBP2/Flag-KIF14). H , ubiquitination assay demonstrating that MYCBP2 enhances the ubiquitination of KIF14. I–J , Cycloheximide (CHX) chase experiment showing prolonged half-life of KIF14 in MYCBP2-knockdown cells. n = 3, mean ± SD; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: MOLM-13 and HL-60 cells (purchased from Wuhan Procell Life Science & Technology Co., Ltd) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, maintained at 37 °C in a 5% CO 2 incubator until reaching 70% to 80 confluence.

Techniques: Ubiquitin Proteomics, Quantitative RT-PCR, Expressing, Knockdown, Western Blot, Co-Immunoprecipitation Assay

Journal: The Journal of Biological Chemistry

Article Title: Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression

doi: 10.1016/j.jbc.2026.112204

Figure Lengend Snippet: MYCBP2 promotes AML progression by suppressing KIF14 . A , downregulation of KIF14 in acute myeloid leukemia (AML) as analyzed using GEPIA. B , Kaplan-Meier survival analysis indicating that high KIF14 expression predicts better overall survival (OS). C , Western Blot validation of KIF14 siRNA knockdown in MOLM-13 and HL-60 cells. D , CCK-8 assay demonstrating that si-KIF14 partially rescues the viability loss induced by MYCBP2 knockdown. E–F , colony formation assay confirming that si-KIF14 reverses the effects of MYCBP2 knockdown. G–H , analysis of apoptosis and cell cycle rescue following KIF14 knockdown. I , Western blot analysis showing restored levels of Cyclin D1, CDK4, and Cyclin E1. n = 3, mean ± SD; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: MOLM-13 and HL-60 cells (purchased from Wuhan Procell Life Science & Technology Co., Ltd) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, maintained at 37 °C in a 5% CO 2 incubator until reaching 70% to 80 confluence.

Techniques: Expressing, Western Blot, Biomarker Discovery, Knockdown, CCK-8 Assay, Colony Assay